Norbert Vey

24.6k total citations · 1 hit paper
402 papers, 10.6k citations indexed

About

Norbert Vey is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Norbert Vey has authored 402 papers receiving a total of 10.6k indexed citations (citations by other indexed papers that have themselves been cited), including 306 papers in Hematology, 106 papers in Molecular Biology and 100 papers in Genetics. Recurrent topics in Norbert Vey's work include Acute Myeloid Leukemia Research (236 papers), Acute Lymphoblastic Leukemia research (92 papers) and Hematopoietic Stem Cell Transplantation (91 papers). Norbert Vey is often cited by papers focused on Acute Myeloid Leukemia Research (236 papers), Acute Lymphoblastic Leukemia research (92 papers) and Hematopoietic Stem Cell Transplantation (91 papers). Norbert Vey collaborates with scholars based in France, United States and Italy. Norbert Vey's co-authors include Thomas Prébet, Didier Blaise, Pierre Fenaux, Mohamad Mohty, Catherine Faucher, Véronique Gelsi‐Boyer, Christian Récher, Christian Chabannon, Julien Mozziconacci and Daniel Olive and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Norbert Vey

394 papers receiving 10.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study

2016 336 citations Emmanuel Raffoux, Norbert Vey et al. profile →

Peers

Countries citing papers authored by Norbert Vey

Since Specialization

Citations

This map shows the geographic impact of Norbert Vey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norbert Vey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norbert Vey more than expected).

Fields of papers citing papers by Norbert Vey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Norbert Vey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norbert Vey. The network helps show where Norbert Vey may publish in the future.

Co-authorship network of co-authors of Norbert Vey

This figure shows the co-authorship network connecting the top 25 collaborators of Norbert Vey. A scholar is included among the top collaborators of Norbert Vey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Norbert Vey. Norbert Vey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CD56neg CD16+ cells represent a distinct mature NK cell subset with altered phenotype and are associated with adverse clinical outcome upon expansion in AML 2025 ·Frontiers in Immunology ·(unknown), Florence Orlanducci, (unknown), (unknown), Amira Ben Amara, (unknown), (unknown), Laurent Gorvel, Nicolas Dulphy, (unknown), Norbert Vey, Daniel Olive, Anne-Sophie Chrétien	2
2	Real-World Multicenter Comparison of Venetoclax and Azacitidine Versus Intermediate or High Dose Cytarabine-Based Salvage for Patients with AML in First Relapse after Front Line Intensive Chemotherapy. a Dataml-IPC-Auraml Consortium Study 2024 ·Blood ·(unknown), Sarah Bertoli, (unknown), Maël Heiblig, Thibaut Leguay, Suzanne Tavitian, Éric Delabesse, (unknown), Emmanuelle Tavernier, Martin Carré, (unknown), Anne Banos, Norbert Vey, (unknown), Christian Récher, Sylvain Garciaz	0
3	Genetic deletion of JAM-C in preleukemic cells rewires leukemic stem cell gene expression program in AML 2024 ·Blood Advances ·(unknown), (unknown), (unknown), Florence Bardin, Maria De Grandis, Véronique Gelsi‐Boyer, (unknown), (unknown), Samuel Granjeaud, Christophe Zemmour, Jean-François Spinella, (unknown), Stéphane J.C. Mancini, Jean‐Marie Boher, Josée Hébert, Guy Sauvageau, Norbert Vey, Juerg Schwaller, Cyril Fauriat, Michel Aurrand‐Lions	1
4	Therapeutic efficacy of platelet transfusion treated with amotosalen/UVA pathogen inactivation technology (INTERCEPT^TM Blood System) in acute myeloid leukemia patients undergoing chemotherapy with curative intent: a single center experience. 2023 ·PubMed ·Patrick Ladaique, (unknown), (unknown), Jacques Chiaroni, Norbert Vey, Christophe Picard, (unknown)	2
5	Prognostic Immune Effector Signature in Adult Acute Lymphoblastic Leukemia Patients Is Dominated by γδ T Cells 2023 ·Cells ·(unknown), (unknown), (unknown), Amira Ben Amara, Florence Orlanducci, Norbert Vey, Laurent Gorvel, Anne-Sophie Chrétien, Daniel Olive	3
6	A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma 2023 ·Hematology ·Robin Noël, Christophe Zemmour, (unknown), (unknown), Thérèse Aurran‐Schleinitz, Diane Coso, (unknown), Lénaïg Mescam, Norbert Vey, (unknown), Borhane Slama, Réda Bouabdallah, Jean‐Marc Schiano de Colella	0
7	GVHD prophylaxis with post-transplant cyclophosphamide results in lower incidence of GVHD and allows faster immunosuppressive treatment reduction compared to antithymocyte globulin in 10/10 HLA-matched unrelated allogeneic hematopoietic cell transplantation 2023 ·Bone Marrow Transplantation ·(unknown), Sabine Fürst, Boris Calmels, Thomas Pagliardini, Samia Harbi, (unknown), (unknown), Claude Lemarié, (unknown), (unknown), Faézeh Legrand, (unknown), Angéla Granata, Pierre Jean Weiller, Christian Chabannon, Jean‐Marc Schiano de Colella, Norbert Vey, Didier Blaise, Raynier Devillier	2
8	Erythroleukemia: Classification 2023 ·SHILAP Revista de lepidopterología ·Nathalie Cervera, Arnaud Guillé, José Adélaı̈de, Sylvain Garciaz, Julien Mozziconacci, Norbert Vey, Véronique Gelsi‐Boyer, Daniel Birnbaum	6
9	Hepatic haemophagocytosis in haematology patients with hepatic dysfunction: prognostic impact and contribution of liver biopsy combined with the haemophagocytic syndrome diagnostic score (HScore) 2022 ·British Journal of Haematology ·(unknown), (unknown), Raynier Devillier, Lionel Galicier, (unknown), Gilles Piana, Flora Poizat, Marion Faucher, Norbert Vey, Frédéric Gonzalez, (unknown), Laurent Chow‐Chine, Antoine Sannini, Djamel Mokart, Colombe Saillard, Magali Bisbal	2
10	Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients 2022 ·Cancers ·Sylvain Garciaz, (unknown), Colombe Saillard, Yosr Hicheri, Bilal Mohty, Jérôme Rey, Evelyne D’Incan, (unknown), (unknown), Valério Maisano, Laura Lombardi, (unknown), Julien Mozziconacci, Véronique Gelsi‐Boyer, Norbert Vey	36
11	In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study 2021 ·Blood Advances ·Raynier Devillier, Édouard Forcade, Alice Garnier, (unknown), Sylvain Thépot, Gaëlle Guillerm, Patrice Céballos, Yosr Hicheri, Pierre‐Yves Dumas, Pierre Péterlin, Mathilde Hunault, Marie C. Béné, Anne Bouvier, Patrice Chevallier, Didier Blaise, Norbert Vey, Arnaud Pigneux, Christian Récher, Anne Huynh	17
12	Prognostic impact of early adjunctive corticosteroid therapy in non-HIV oncology or haematology patients with Pneumocystis jirovecii pneumonia: A propensity score analysis 2021 ·PLoS ONE ·(unknown), Jérôme Lambert, Laurent Chow‐Chine, Magali Bisbal, (unknown), Frédéric Gonzalez, (unknown), Marion Faucher, Norbert Vey, Antoine Sannini, Djamel Mokart	15
13	JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid Leukemia 2017 ·Cancer Research ·Maria De Grandis, Florence Bardin, Cyril Fauriat, Christophe Zemmour, Abdessamad El-Kaoutari, Arnauld Sergé, Samuel Granjeaud, Laurent Pouyet, Camille Montersino, Anne-Sophie Chrétien, Julien Mozziconacci, Rémy Castellano, Ghislain Bidaut, Jean‐Marie Boher, Yves Collette, Stéphane J.C. Mancini, Norbert Vey, Michel Aurrand‐Lions	18
14	Frequency and Dynamics of Leukemia-Initiating Cells during Short-term Ex Vivo Culture Informs Outcomes in Acute Myeloid Leukemia Patients 2016 ·Cancer Research ·Emmanuel Griessinger, Fernando Anjos‐Afonso, Jacques Vargaftig, David Taussig, François Lassailly, Thomas Prébet, Véronique Imbert, Marielle Nebout, Norbert Vey, Christian Chabannon, Andrew Filby, (unknown), John G. Gribben, Jean‐François Peyron, Dominique Bonnet	19
15	Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia 2016 ·Leukemia & lymphoma ·Norbert Vey, Thomas Prébet, Claire Thalamas, Aude Charbonnier, Jérôme Rey, Ioana Kloos, Emily Liu, Ying Luan, Remus Vezan, Thorsten Graef, Christian Récher	15
16	Outcome of Acute Promyelocytic Leukemia (APL) in Children and Adolescents: An Analysis in Two Consecutive Trials of the European APL Group 2012 ·Journal of Clinical Oncology ·Cécile Bally, Jehane Fadlallah, Guy Leverger, Yves Bertrand, Alain Robert, André Baruchel, Agnès Guerci, Christian Récher, Emmanuel Raffoux, Xavier Thomas, Thierry Leblanc, Nadia Idres, Bruno Cassinat, Norbert Vey, Christine Chomienne, Hervé Dombret, Miguel Á. Sanz, Pierre Fenaux, Lionel Adès	32
17	Bortezomib combined with low‐dose cytarabine in Intermediate‐2 and high risk myelodysplastic syndromes. A phase I / II Study by the GFM 2012 ·British Journal of Haematology ·Shanti Natarajan‐Amé, Sophie Park, Lionel Adès, Norbert Vey, Agnès Guerci‐Bresler, Jean‐Yves Cahn, Gabriel Étienne, Dominique Bordessoule, Christophe Ravoet, Laurence Legros, Stéphane Chèze, Aspasia Stamatoullas, É. Berger, Aline Schmidt, Aude Charbonnier, (unknown), Thorsten Braun, Pierre Fenaux, François Dreyfus, (unknown)	12
18	Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study 2008 ·Blood ·Lionel Adès, Simone Boehrer, Thomas Prébet, Odile Beyne‐Rauzy, Laurence Legros, Christophe Ravoet, François Dreyfus, Aspasia Stamatoullas, (unknown), Jacques Delaunay, Laurent Guy, Norbert Vey, Sara Burcheri, (unknown), (unknown), Claude Gardin, Pierre Fenaux	107
19	Re: Familial multiple myeloma: A family study and review of the literature (multiple letters) 2002 ·JNCI Journal of the National Cancer Institute ·Hagay Sobol, Norbert Vey, R Sauvan, Nicole Philip, Tetsuro Noguchi, François Eisinger, Kari Hemminki, Henry T. Lynch, Warren G. Sanger, Samuel J. Pirruccello, (unknown), Dennis D. Weisenburger	8
20	Autologous Transplantation of Blood Stern Cells Mobilized with Filgrastim Alone in 93 Patients with Malignancies: The Number of CD34+ Cells Reinfused Is the Only Factor Predicting Both Granulocyte and Platelet Recovery 1996 ·Journal of Hematotherapy ·Catherine Faucher, Anne‐Gaëlle Le Corroller, Christian Chabannon, Patrice Viens, A. M. Stoppa, Réda Bouabdallah, Jacques Camerlo, Norbert Vey, Gwénaëlle Gravis, J.A. Gastaut, D Maraninchi, Didier Blaise	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact